These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39043643)

  • 1. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity.
    Ye QN; Zhu L; Liang J; Zhao DK; Tian TY; Fan YN; Ye SY; Liu H; Huang XY; Cao ZT; Shen S; Wang J
    Nat Commun; 2024 Jul; 15(1):6211. PubMed ID: 39043643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.
    Jiang CT; Chen KG; Liu A; Huang H; Fan YN; Zhao DK; Ye QN; Zhang HB; Xu CF; Shen S; Xiong MH; Du JZ; Yang XZ; Wang J
    Nat Commun; 2021 Mar; 12(1):1359. PubMed ID: 33649336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
    André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
    Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
    Chester C; Ambulkar S; Kohrt HE
    Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.
    Alvarez M; Bouchlaka MN; Sckisel GD; Sungur CM; Chen M; Murphy WJ
    J Immunol; 2014 Aug; 193(4):1709-16. PubMed ID: 25000978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
    Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
    Maniar A; Zhang X; Lin W; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Blood; 2010 Sep; 116(10):1726-33. PubMed ID: 20519625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
    J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT-Fc Promotes Antitumor Immunity.
    Shen X; Fu W; Wei Y; Zhu J; Yu Y; Lei C; Zhao J; Hu S
    Cancer Immunol Res; 2021 Sep; 9(9):1088-1097. PubMed ID: 34244300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.